Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex).
The effects of the novel benzimidazole, triclabendazole (Fasinex, Ciba-Geigy), in its active sulphoxide metabolite form (TCBZ-SX), on the tegumental surface of Fasciola hepatica has been examined in vitro. The tegument of adult flukes incubated in TCBZ-SX (50 micrograms/ml) appeared swollen and blebbed after only 6 h. In addition, progressive spine loss at the oral cone was evident following 12 h treatment. After 24 h, the tegumental syncytium and spines had completely sloughed away, leaving an exposed basal lamina and empty spine sockets. Juvenile flukes (3 weeks old) also demonstrated tegumental alterations after treatment with TCBZ-SX (20 micrograms/ml). The syncytium became extremely roughened and corrugated on both dorsal and ventral surfaces after only 3 h. Following 6- and 9-h incubations, there were many deep furrows, which were especially pronounced on the ventral surface, and by 18 h, the juvenile tegument was severely disrupted, especially on the ventral surface. In all cases, the effects were more marked than in the previous incubation periods. The results confirm the potent activity of triclabendazole against F. hepatica and suggest that the tegument of adult and juvenile flukes may be a target organ for this important fasciolicide.
Stitt
A W
AW
School of Biology and Biochemistry, Queen's University of Belfast, Northern Ireland.
Fairweather
I
I
D000375:Aging; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D004817:Epidermis / Q000187:drug effects / Q000648:ultrastructure; D005210:Fasciola hepatica / Q000187:drug effects* / Q000648:ultrastructure; D008855:Microscopy, Electron, Scanning; D051381:Rats; D017208:Rats, Wistar; D013454:Sulfoxides / Q000494:pharmacology*; D000077682:Triclabendazole
D000871:Anthelmintics; D001562:Benzimidazoles; D013454:Sulfoxides; D000077682:Triclabendazole; C085104:triclabendazole sulfoxide